<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24815">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783716</url>
  </required_header>
  <id_info>
    <org_study_id>15-006402</org_study_id>
    <nct_id>NCT02783716</nct_id>
  </id_info>
  <brief_title>Vascular Endothelial Function and Cardiac Resynchronization Response in Patients With Heart Failure</brief_title>
  <official_title>Vascular Endothelial Function and Cardiac Resynchronization Response in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine the role of vascular endothelial function in heart
      failure (HF) and the effect of cardiac resynchronization therapy (CRT) on endothelial and
      cardiac function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in vascular endothelial function</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>Vascular endothelial function will be measured using peripheral arterial tonometry as the reactive hyperemia index (RHI) at baseline and at 3 months.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Cardiac Resynchronization Therapy (CRT) implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will received Cardiac Resynchronization Therapy Implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac Resynchronization Therapy Implantation</intervention_name>
    <arm_group_label>Cardiac Resynchronization Therapy (CRT) implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients recommended for CRT-P or CRT-D for heart failure (HF) according to current
             American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm
             Society (HRS) guidelines of Left Ventricle Ejection Fraction (LVEF)&lt;35%, Left Bundle
             Branch Block (LBBB)&gt;120 ms, New York Heart Association (NYHA) Class II-III).

        Exclusion Criteria:

          -  Patients who are unwilling or unable to return for follow up visits 3 months after
             device implantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hon-Chi Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica V Bauman</last_name>
    <phone>507-266-1123</phone>
    <email>bauman.jessica@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hon-Chi Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yong-Mei Cha, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Lerman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 23, 2016</lastchanged_date>
  <firstreceived_date>May 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Hon-Chi Lee, M.D., Ph.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
